基线代谢肿瘤负荷可改善霍奇金淋巴瘤的风险分层:儿童肿瘤协作组研究
儿童肿瘤协作组AHOD0831研究在高危霍奇金淋巴瘤中采用PET反应适应策略,慢速早期反应者接受更强治疗。166例入组患者中94例基线PET可定量分析,TLG2.5与无事件生存相关,TLG2.5≤1841的快速早期反应者4年EFS达92%。
要点
- TLG2.5与全体队列及快速早期反应者的无事件生存相关,与慢速早期反应者无关。
- TLG2.5的Youden指数截断值为1841。
- 快速早期反应者中TLG2.5≤1841者4年EFS为92%,TLG2.5>1841者为60%。
核心结论
- 基线TLG2.5低的快速早期反应者接受较弱治疗即获得极好无事件生存,而TLG2.5高者无事件生存差。
- 作者认为基线肿瘤负荷高的患者即使达到快速早期反应,也可能从强化治疗中获益。
研究设计与样本
- 儿童肿瘤协作组AHOD0831研究采用PET反应适应策略,慢速早期反应者接受比快速早期反应者更强的治疗。
- 166例入组患者中94例(57%)基线PET可定量分析,获取全身代谢肿瘤体积、总病灶糖酵解、最大标准化摄取值和峰值标准化摄取值。
主要发现
- TLG2.5与全体队列的无事件生存相关(p=0.04),与快速早期反应者相关(p=0.01),与慢速早期反应者无关(p=0.8)。
- TLG2.5的Youden指数截断值为1841。
- 4年无事件生存:快速早期反应者/TLG2.5≤1841为92%,快速早期反应者/TLG2.5>1841为60%,慢速早期反应者/TLG2.5≤1841为74%,慢速早期反应者/TLG2.5>1841为79%。
- 快速早期反应者/TLG2.5≤1841的第二次无事件生存为100%。
关键数值与推荐
- MTV/TLG阈值采用标准化摄取值2.5(MTV2.5/TLG2.5)和肿瘤最大标准化摄取值40%(MTV40%/TLG40%)。
- TLG2.5的Youden指数截断值为1841。
临床怎么用
- 原文未据此给出推荐。
局限性
- 166例入组患者中仅94例(57%)基线PET可定量分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Children's Oncology Group AHOD0831 study used a positron emission tomography (PET) response-adapted approach in high-risk Hodgkin lymphoma, whereby slow early responders (SERs) received more intensive therapy than rapid early responders (RERs). We explored if baseline PET-based characteristics would improve risk stratification. Of 166 patients enrolled in the COG AHOD0831 study, 94 (57%) had baseline PET scans evaluable for quantitative analysis. For these patients, total body metabolic tumour volume (MTV), total lesion glycolysis (TLG), maximum standardized uptake value (SUVmax ) and peak SUV (SUVpeak ) were obtained. MTV/TLG thresholds were an SUV of 2.5 (MTV2.5 /TLG2.5 ) and 40% of the tumour SUVmax (MTV40% /TLG40% ). TLG2.5 was associated with event-free survival (EFS) in the complete cohort (p = 0.04) and in RERs (p = 0.01), but not in SERs (p = 0.8). The Youden index cut-off for TLG2.5 was 1841. Four-year EFS was 92% for RER/TLG2.5 up to 1841, 60% for RER/TLG2.5 greater than 1841, 74% for SER/TLG2.5 up to 1841 and 79% for SER/TLG2.5 greater than 1841. Second EFS for RER/TLG2.5 up to 1841 was 100%. Thus, RERs with a low baseline TLG2.5 experienced excellent EFS with less intensive therapy, whereas RERs with a high baseline TLG2.5 experienced poor EFS. These findings suggest that patients with a high upfront tumour burden may benefit from intensified therapy, even if they achieve a RER.
引用
- Milgrom SA, Kim J, Pei Q, et al. Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study. Br J Haematol. 2023. PMID: 36922022. doi:10.1111/bjh.18734
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。